Maxim Group Reiterates “$4.00” Price Target for Interpace Diagnostics Group (IDXG)

Maxim Group set a $4.00 target price on Interpace Diagnostics Group (NASDAQ:IDXG) in a report published on Wednesday morning. The firm currently has a buy rating on the business services provider’s stock.

Other analysts also recently issued reports about the company. HC Wainwright set a $3.00 price target on Interpace Diagnostics Group and gave the company a buy rating in a research note on Friday, August 10th. ValuEngine upgraded Interpace Diagnostics Group from a sell rating to a hold rating in a research report on Friday, August 10th. Dawson James started coverage on Interpace Diagnostics Group in a research report on Wednesday, October 17th. They set a buy rating and a $4.00 target price on the stock. Finally, Zacks Investment Research upgraded Interpace Diagnostics Group from a hold rating to a buy rating and set a $1.25 target price on the stock in a research report on Wednesday, August 22nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $3.17.

Shares of Interpace Diagnostics Group stock traded up $0.02 during trading on Wednesday, reaching $1.53. The company’s stock had a trading volume of 419,331 shares, compared to its average volume of 249,441. Interpace Diagnostics Group has a 12-month low of $0.77 and a 12-month high of $1.78. The company has a market cap of $40.42 million, a PE ratio of -1.89 and a beta of 2.26.

Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings results on Thursday, August 9th. The business services provider reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. Interpace Diagnostics Group had a negative return on equity of 34.58% and a negative net margin of 71.14%. The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $4.80 million. Research analysts expect that Interpace Diagnostics Group will post -0.31 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in Interpace Diagnostics Group during the third quarter worth $194,000. Perkins Capital Management Inc. purchased a new stake in Interpace Diagnostics Group during the third quarter worth $983,000. Finally, Essex Investment Management Co. LLC purchased a new stake in Interpace Diagnostics Group during the third quarter worth $465,000. Institutional investors own 15.59% of the company’s stock.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

See Also: Buyback

Analyst Recommendations for Interpace Diagnostics Group (NASDAQ:IDXG)

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply